Now showing items 1-1 of 1

    • Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. 

      Poon, E; Liang, T; Jamin, Y; Walz, S; Kwok, C; Hakkert, A; Barker, K; Urban, Z; Thway, K; Zeid, R; Hallsworth, A; Box, G; Ebus, ME; Licciardello, MP; Sbirkov, Y; Lazaro, G; Calton, E; Costa, BM; Valenti, M; De Haven Brandon, A; Webber, H; Tardif, N; Almeida, GS; Christova, R; Boysen, G; Richards, MW; Barone, G; Ford, A; Bayliss, R; Clarke, PA; De Bono, J; Gray, NS; Blagg, J; Robinson, SP; Eccles, SA; Zheleva, D; Bradner, JE; Molenaar, J; Vivanco, I; Eilers, M; Workman, P; Lin, CY; Chesler, L (2020-11)
      The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show ...